Jia Sheng Tay

Jia Sheng Tay

Auto-generated profile, based on publicly available information

Jia Sheng Tay

Sengkang General Hospital, Singapore

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
ECEdward Choke
Edward Choke
TTTjun Yip Tang
Tjun Yip Tang
EPEilane Peh
Eilane Peh
KDKarthikeyan Damodharan
Karthikeyan Damodharan
SCShin Chuen Cheng
Shin Chuen Cheng
AFAloke V. Finn
Aloke V. Finn
Sirolimus coated balloon (SCB) is a promising treatment option to prevent restenosis for peripheral arterial occlusive disease (PAOD). This is a pilot first-in-human study of MagicTouch percutaneous transluminal angioplasty (PTA) SCB for treatment of PAOD for both femoropopliteal and below the knee arteries (BTK). Xtreme Touch-Neo [MagicTouch PTA] Sirolimus Coated Balloon (XTOSI) pilot study is a prospective, single-arm, open-label, single-center trial evaluating MagicTouch PTA SCB for symptomatic PAOD. Primary endpoint was defined as primary patency at 6 months (duplex ultrasound peak systolic velocity ratio ≤2.4). Secondary endpoints included clinically driven target lesion revascularization (CD-TLR), amputation free survival (AFS), all-cause mortality, and limb salvage success. Fifty patients were recruited. The mean age was 67 (n=31 [62%] males). SCB was applied to femoropopliteal in 20 patients (40%) and BTK in 30 patients (60%). Majority of treatments (94%) were performed for limb salvage indications (Rutherford scores 5 or 6). This was a high risk cohort, in which 90% had diabetes, 36% had coronary artery disease, 20% had end stage renal failure, and American Society of Anaesthesiologists (ASA) score was 3 or more in 80%. Mean lesion length treated was 227±81 mm, of which 36% were total occlusions. Technical and device success were both 100%. At 30 days, mortality was 2% and major limb amputation was also 2%. Six-month primary patency was 80% (88.2% for femoropopliteal; 74% for BTK). At 12 months, freedom from CD-TLR was 89.7% (94.1% for femoropopliteal; 86.3% for BTK), AFS was 81.6% (90.0% for femoropopliteal; 75.9% for BTK), all-cause mortality was 14.3% (10.0% for femoropopliteal; 17.2% for BTK), and limb salvage success was 92.9% (94.4% for femoropopliteal; 91.7% for BTK). There was a statistically significant increase between baseline and 6-month toe pressures for both femoropopliteal (57.3±23.3 mm Hg vs 82.5±37.8 mm Hg; p<.001) and BTK lesions (52.8±19.2 mm Hg vs 70.7±37 mm Hg; p<.037). At 12 months, wound healing rate was 33/39 (84.6%). MagicTouch PTA SCB in the XTOSI study showed promising 6-month primary patency and encouraging 12-month freedom from CD-TLR, AFS, and limb salvage rates. No early safety concerns were raised. Randomized trials are needed to investigate the safety and efficacy of SCB for treatment of PAOD.

1 June 2021 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
CPC.Y. Maximilian Png
C.Y. Maximilian Png
JWJingting Wu
Jingting Wu
TTTjun Y. Tang
Tjun Y. Tang
IPIvan P.L. Png
Ivan P.L. Png
TSTay J. Sheng
Tay J. Sheng
ECEdward Choke
Edward Choke

3 April 2024 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
ECEdward Choke
Edward Choke
EPEilane Yi Ling Peh
Eilane Yi Ling Peh
TTTjun Yip Tang
Tjun Yip Tang
SCShin Chuen Cheng
Shin Chuen Cheng
JTJia Sheng Tay
Jia Sheng Tay
KVKalpana Vijaykumar
Kalpana Vijaykumar

12 December 2019 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
PDF file
ECEdward Choke
Edward Choke
TTTjun Y. Tang
Tjun Y. Tang
SCShin C. Cheng
Shin C. Cheng
JTJia S. Tay
Jia S. Tay
Diabetic chronic limb‐threatening ischaemia is a challenging clinical problem with patients at high risk of diabetic foot ulceration (DFU) and limb loss. Patients often remain asymptomatic even in the presence of severe pedal ischaemia until first presenting with tissue loss such as DFU or frank gangrene. Limb salvage units should have the facilities and expertise to provide multidisciplinary team‐based holistic care through best medical therapy, rapid diagnosis, prompt revascularisation with endovascular or open surgical techniques and expert wound management. Endovascular revascularisation has become the first line strategy in contemporary clinical practice because of similar outcomes in wound healing and amputation rates in most patients when compared with open surgery. The primary goal is restoration of pulsatile in‐line blood flow to the ankle or foot, with an angiosome‐directed approach possibly achieving superior outcomes especially in diabetics with poor collaterals. A comprehensive overview of conventional endovascular techniques (such as antegrade true lumen and subintimal approaches), advanced techniques for complex disease (such as retrograde subintimal and pedal‐plantar loop approaches or even deep venous arterialisation) and the various treatment options are described. Diabetic limb salvage rates can be excellent with suitable multidisciplinary expertise and care.

20 December 2021 in Trials
Verified
Journal Article
Open access
PDF file
SPSuh Chien Pang
Suh Chien Pang
RTRu Yu Tan
Ru Yu Tan
ECEdward Choke
Edward Choke
JHJackie Ho
Jackie Ho
KTKiang Hiong Tay
Kiang Hiong Tay
CTChieh Suai Tan
Chieh Suai Tan
Background: Percutaneous transluminal angioplasty is the current standard treatment for arteriovenous fistula (AVF) stenosis. The mid- and long-term patency with plain balloon angioplasty (PBA) is however far from satisfactory. While paclitaxel-coated balloon angioplasty has been shown to be superior to PBA, concern over its safety profile has recently arisen after a reported possible increased mortality risk with a meta-analysis of large lower limb studies. An angioplasty balloon with a new type of drug coating, the sirolimus-coated balloon (SCB), has been proven to improve patency in the coronary arteries. However, its effect on AV access has yet to be studied. Methods/design: This is an investigator-initiated, prospective, multicenter, double-blinded, randomized controlled clinical trial to assess the effectiveness of SCB compared to PBA in improving the patency of AVF after angioplasty. A total of 170 patients with mature AVF that requires PTA due to AVF dysfunction will be randomly assigned to treatment with a SCB or PBA at a 1:1 ratio, stratified by location of AVF and followed up for up to 1 year. The inclusion criteria include [1] adult patient aged 21 to 85 years who requires balloon angioplasty for dysfunctional arteriovenous fistula [2]; matured AVF, defined as being in use for at least 1 month prior to the angioplasty; and [3] successful angioplasty of the underlying stenosis with PBA, defined as less than 30% residual stenosis on digital subtraction angiography (DSA) and restoration of thrill in the AVF on clinical examination. The exclusion criteria include thrombosed or partially thrombosed access circuit at the time of treatment, presence of symptomatic or angiographically significant central vein stenosis that requires treatment with more than 30% residual stenosis post angioplasty, and existing stent placement within the AVF circuit. The primary endpoint of the study is access circuit primary patency at 6 months. The secondary endpoints are target lesion primary patency; access circuit-assisted primary patency; access circuit secondary patency at 3, 6, and 12 months; target lesion restenosis rate at 6 months; total number of interventions; complication rate; and cost-effectiveness. The trial is supported by Concept Medical. Discussion: This study will evaluate the clinical efficacy and safety of SCB compared to PBA in the treatment of AVF stenosis in hemodialysis patients. Trial registration: ClinicalTrials.gov NCT04409912. Registered on 1 June 2020

3 June 2016 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JTJia Sheng Tay
Jia Sheng Tay
SCSiok Siong Ching
Siok Siong Ching
YTYih Kai Tan
Yih Kai Tan
SKSteven Wei Cheong Kum
Steven Wei Cheong Kum